Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30655830 | 1.00 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL30262409 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL30262408 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13 | |
| Silver SCHEMBL4197236 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31629814 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL6031301 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL432957 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31279954 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31721030 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| Potassium Ion SCHEMBL878391 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617889-B1 | Polymers for use as anion exchange membranes | ENVISION ENERGY USA LTD. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4706123-A2 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | Feon Energy, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260024750-A1 | SILICON ANODES HAVING ENHANCED ELECTRONIC CONDUCTIVITY AND SPECIFIC CAPACITY | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2026-01-22 | — | — | US | claimed |
| US-20250201917-A1 | ELECTROLYTES INCLUDING OXALATE-BASED ADDITIVES FOR BATTERIES THAT CYCLE LITHIUM IONS AND BATTERIES INCLUDING THE SAME | GM Global Technology Operations LLC | 2025-06-19 | — | — | US | claimed |
| WO-2024226580-A9 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. (US) | 2025-03-27 | — | — | WO | claimed |
| WO-2024226580-A2 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. (US) | 2024-10-31 | — | — | WO | claimed |
| US-20240360062-A1 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. | 2024-10-31 | — | — | US | claimed |
| WO-2024173681-A1 | SILYL ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240258572-A1 | ELECTROLYTES FOR LITHIUM-RICH, LAYERED CATHODES | GM Global Technology Operations LLC (US) | 2024-08-01 | — | — | US | claimed |
| US-20240170648-A1 | METAL SALT COMPOSITE CATHODES FOR METAL AND METAL ION BATTERIES | OREGON STATE UNIVERSITY (US) | 2024-05-23 | — | — | US | claimed |
| US-20240057359-A1 | SOLAR CELL AND METHOD OF PRODUCING SOLAR CELL | PANASONIC HOLDINGS CORPORATION (JP) | 2024-02-15 | — | — | US | claimed |
| US-11876184-B2 | Electrolyte medium for lithium secondary battery and lithium secondary battery | HONDA MOTOR CO., LTD. (JP) | 2024-01-16 | — | — | US | claimed |
| US-20240006660-A1 | ELECTROLYTE ADDITIVES FOR LITHIUM-RICH, LAYERED CATHODES | GM Global Technology Operations LLC (US) | 2024-01-04 | — | — | US | claimed |
| CN-115960056-A | Novel method for synthesizing para-substituted aniline compound | 复旦大学 | 2023-04-14 | — | — | CN | claimed |
| US-20230074112-A1 | POLYMERIC GEL ELECTROLYTE SYSTEMS FOR HIGH-POWER SOLID-STATE BATTERY | GM Global Technology Operations LLC (US) | 2023-03-09 | — | — | US | claimed |
| WO-2022244413-A1 | SOLAR CELL AND METHOD FOR MANUFACTURING SOLAR CELL | パナソニックホールディングス株式会社 | 2022-11-24 | — | — | WO | claimed |
| WO-2022244336-A1 | SOLAR CELL AND SOLAR CELL MANUFACTURING METHOD | パナソニックホールディングス株式会社 | 2022-11-24 | — | — | WO | claimed |
| US-11393640-B2 | Water based hybrid lithium ion capacitor battery having a water-in-salt electrolyte | GM Global Technology Operations LLC (US) | 2022-07-19 | — | — | US | claimed |
| US-20220085415-A1 | ELECTROLYTE MEDIUM FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY | SAITAMA PREFECTURE (JP) | 2022-03-17 | — | — | US | claimed |
| US-20070122706-A1 | Nonaqueous electrolyte battery | INOUE TAKAO | 2007-05-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360062-A1 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | SLC26A3, CLCN2, SLC26A4 | CA1 561/4885CA2 473/4885CA7 394/4885 |
| US-12617889-B1 | Polymers for use as anion exchange membranes | KCNN3, KCNJ1, KCNH3 | CA1 267/4885CA2 87/4885CA7 362/4885 |
| US-20260024750-A1 | SILICON ANODES HAVING ENHANCED ELECTRONIC CONDUCTIVITY AND SPECIFIC CAPACITY | SIK1, SIK2, KCNN2 | CA1 310/4885CA2 394/4885CA7 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.